A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
This study is designed to compare the efficacy of intraperitoneal paclitaxel in combination with SOX, with SOX alone in the first-line treatment of gastric cancer with malignant ascites
Gastric Cancer|Stomach Neoplasms
DRUG: Oxaliplatin|DRUG: Paclitaxel|DRUG: S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)
overall survival, the internal between the date of enrollment and the date of death or last follow-up., 10 months
This study is designed to compare the efficacy of intraperitoneal paclitaxel in combination with SOX, with SOX alone in the first-line treatment of gastric cancer with malignant ascites